Pre-Open Movers 07/23: (CBAY) (NTGR) (HZO) Higher; (LLNW) (ALGN) (MSFT) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Twitter, Inc. (TWTR) PT Raised to $40 at Canaccord Genuity
July 24, 2020 8:08 AM EDTCanaccord Genuity analyst Maria Ripps raised the price target on Twitter, Inc. (NYSE: TWTR) to $40.00 (from $32.00) while maintaining a Hold rating following the company's 2Q. Twitter's Q2 results showed a continued acceleration of user growth, up to a record~34% y/y (vs. +24% in Q1),... More
Twitter, Inc. (TWTR) PT Raised to 'Street High' $50 at Susquehanna
July 24, 2020 6:25 AM EDTSusquehanna analyst Shyam Patil raised the price target on Twitter, Inc. (NYSE: TWTR) to a 'Street High' $50.00 (from $35.00) while maintaining a Positive rating with mDAUs impress and ad revenue recovery better than feared.
Patil commented, "TWTR continues to see a gradual... More
MarineMax (HZO) PT Raised to $30 at Wedbush
July 23, 2020 3:37 PM EDTWedbush analyst James Hardiman raised the price target on MarineMax (NYSE: HZO) to $30.00 (from $23.00) while maintaining a Neutral rating.
Boat Sales Leap Past Even Raised Expectations... MoreCantor Fitzgerald Said 'Just the Beginning' of CymaBay Therapeutic (CBAY) Share Recovery After FDA Hold Lifted
July 23, 2020 10:35 AM EDTCantor Fitzgerald analyst Eliana Merle reiterated an Overweight rating and $15.00 price target on CymaBay Therapeutic (NASDAQ: CBAY) after the clinical hold on seladelpar was lifted. The analyst thinks this is just the beginning of a major recovery for shares.
Merle commented, "This morning CBAY announced the FDA lifted the clinical hold on seladelpar across all indications (PBC, PSC, NASH). This is a... More
